Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting

References

• Kulik L, El-Serag HB. Epidemiology and management of hepatocellular carcinoma. Gastroenterology 2019;156:477–491.e1.
   PubMed Web of Science ®Google Scholar
• Edenvik P, Davidsdottir L, Oksanen A, et al. Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice? Liver Int. 2015;35:1862–1871.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182–236.
   PubMed Web of Science ®Google Scholar
• Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391:1301–1314.
   PubMed Web of Science ®Google Scholar
• Facciorusso A, Licinio R, Muscatiello N, et al. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. WJH. 2015;7:2009–2019.
   PubMedGoogle Scholar
• Lencioni R, Petruzzi P, Crocetti L. Chemoembolization of hepatocellular carcinoma. Semin Inter Rad. 2013;30:3–11.
   PubMed Web of Science ®Google Scholar
• Marelli L, Stigliano R, Triantos C, et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Inter Rad. 2007;30:6–25.
   PubMed Web of Science ®Google Scholar
• Raoul JL, Sangro B, Forner A, et al. Evolving strategies for the management of intermediate-stage hepatocellular carcinoma: available evidence and expert opinion on the use of transarterial chemoembolization. Cancer Treat Rev. 2011;37:212–220.
   PubMed Web of Science ®Google Scholar
• Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474–481.
   PubMed Web of Science ®Google Scholar
• Reyes DK, Vossen JA, Kamel IR, et al. Single-center phase II trial of transarterial chemoembolization with drug-eluting beads for patients with unresectable hepatocellular carcinoma: initial experience in the United States. Cancer J. 2009;15:526–532.
   PubMed Web of Science ®Google Scholar
• Lencioni R, de Baere T, Burrel M, et al. Transcatheter treatment of hepatocellular carcinoma with Doxorubicin-loaded DC Bead (DEBDOX): technical recommendations. Cardiovasc Inter Rad. 2012;35:980–985.
   PubMed Web of Science ®Google Scholar
• Lilienberg E, Dubbelboer IR, Karalli A, et al. In vivo drug delivery performance of lipiodol-based emulsion or drug-eluting beads in patients with hepatocellular carcinoma. Mol Pharm. 2017;14:448–458.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran R, Kooby DA, Staley CA, et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol. 2010;101:476–480.
   PubMed Web of Science ®Google Scholar
• Nicolini D, Svegliati BG, Candelari R, et al. Doxorubicin-eluting bead vs conventional transcatheter arterial chemoembolization for hepatocellular carcinoma before liver transplantation. WJG. 2013;19:5622–5632.
   PubMed Web of Science ®Google Scholar
• Wiggermann P, Sieron D, Brosche C, et al. Transarterial Chemoembolization of Child-A hepatocellular carcinoma: drug-eluting bead TACE (DEB TACE) vs. TACE with cisplatin/lipiodol (cTACE). Med Sci Monit. 2011;17:CR189–95.
   PubMed Web of Science ®Google Scholar
• Arabi M, BenMousa A, Bzeizi K, et al. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma. Saudi J Gastroenterol. 2015;21:175–180.
   PubMed Web of Science ®Google Scholar
• Liu YS, Ou MC, Tsai YS, et al. Transarterial chemoembolization using gelatin sponges or microspheres plus lipiodol-doxorubicin versus doxorubicin-loaded beads for the treatment of hepatocellular carcinoma. Korean J Radiol. 2015;16:125–132.
   PubMed Web of Science ®Google Scholar
• Megias Vericat JE, Garcia Marcos R, Lopez Briz E, et al. Trans-arterial chemoembolization with doxorubicin-eluting particles versus conventional trans-arterial chemoembolization in unresectable hepatocellular carcinoma: a study of effectiveness, safety and costs. Radiologia 2015;57:496–504.
   PubMed Web of Science ®Google Scholar
• Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolisation (TACE) using drug eluting beads. implications for clinical practice and trial design. J Hepatol. 2012;56:1330–1335.
   PubMed Web of Science ®Google Scholar
• Kloeckner R, Weinmann A, Prinz F, et al. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma. BMC Cancer 2015;15:465.
   PubMed Web of Science ®Google Scholar
• Scartozzi M, Baroni GS, Faloppi L, et al. Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysis. J Exp Clin Cancer Res. 2010;29:164.
   PubMed Web of Science ®Google Scholar
• Golfieri R, Giampalma E, Renzulli M, et al. Randomised controlled trial of doxorubicin-eluting beads vs conventional chemoembolisation for hepatocellular carcinoma. Br J Cancer. 2014;111:255–264.
   PubMed Web of Science ®Google Scholar
• Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Inter Rad. 2010;33:41–52.
   PubMed Web of Science ®Google Scholar
• Sacco R, Bargellini I, Bertini M, et al. Conventional versus doxorubicin-eluting bead transarterial chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol. 2011;22:1545–1552.
   PubMed Web of Science ®Google Scholar
• van Malenstein H, Maleux G, Vandecaveye V, et al. A randomized phase II study of drug-eluting beads versus transarterial chemoembolization for unresectable hepatocellular carcinoma. Onkologie. 2011;34:368–376.
   PubMedGoogle Scholar
• Cheng AL, Amarapurkar D, Chao Y, et al. Re-evaluating transarterial chemoembolization for the treatment of hepatocellular carcinoma: Consensus recommendations and review by an International Expert Panel. Liver Int. 2014;34:174–183.
   PubMed Web of Science ®Google Scholar
• Massani M, Stecca T, Ruffolo C, et al. Should we routinely use DEBTACE for unresectable HCC? cTACE versus DEBTACE: a single-center survival analysis. Updates Surg. 2017;69:67–73.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol. 2001;35:421–430.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Practice Guidelines Committee A. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–1236.
   PubMed Web of Science ®Google Scholar
• Forner A, Vilana R, Ayuso C, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 2008;47:97–104.
   PubMed Web of Science ®Google Scholar
• Bonder A, Afdhal N. Utilization of FibroScan in clinical practice. Curr Gastroenterol Rep. 2014;16:372
   PubMedGoogle Scholar
• Liu YS, Lin CY, Chuang MT, et al. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. BMC Gastroenterol. 2018;18:124
   PubMed Web of Science ®Google Scholar
• Song MJ, Chun HJ, Song DS, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012;57:1244–1250.
   PubMed Web of Science ®Google Scholar
• Fako V, Wang XW. The status of transarterial chemoembolization treatment in the era of precision oncology. Hepat Oncol. 2017;4:55–63.
   PubMed Web of Science ®Google Scholar
• Huang K, Zhou Q, Wang R, et al. Doxorubicin-eluting beads versus conventional transarterial chemoembolization for the treatment of hepatocellular carcinoma. J Gastroenterol Hepatol. 2014;29:920–925.
   PubMed Web of Science ®Google Scholar
• Zou JH, Zhang L, Ren ZG, et al. Efficacy and safety of cTACE versus DEB-TACE in patients with hepatocellular carcinoma: a meta-analysis. J Dig Dis. 2016;17:510–517.
   PubMed Web of Science ®Google Scholar
• Facciorusso A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: current state of the art. WJG. 2018;24:161–169.
   PubMed Web of Science ®Google Scholar
• Gao S, Yang Z, Zheng Z, et al. Doxorubicin-eluting bead versus conventional TACE for unresectable hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology. 2013;60:813–820.
   PubMedGoogle Scholar
• Han S, Zhang X, Zou L, et al. Does drug-eluting bead transcatheter arterial chemoembolization improve the management of patients with hepatocellular carcinoma? A meta-analysis. PloS One. 2014;9:e102686.
   PubMed Web of Science ®Google Scholar
• Martin R, Geller D, Espat J, et al. Safety and efficacy of trans arterial chemoembolization with drug-eluting beads in hepatocellular cancer: a systematic review. Hepatogastroenterology. 2012;59:255–260.
   PubMedGoogle Scholar
• Brown KT, Do RK, Gonen M, et al. Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone. JCO. 2016;34:2046–2053.
   PubMed Web of Science ®Google Scholar
• Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–1739.
   PubMed Web of Science ®Google Scholar
• Liu F, Meng Z, Shao G, et al. Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study. Mol Biol Rep. 2017;44:149–158.
   PubMed Web of Science ®Google Scholar